跳至主要内容
临床试验/NCT02999152
NCT02999152终止不适用

Validation of Radio-induced Damage Biomarkers : BIOM-DRI Study

Centre Hospitalier Universitaire de Saint Etienne4 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2017年6月22日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
16
试验地点
4
主要终点
Level of haematological and biochemical markers

研究概览

简要总结

The aim of this study is to confirm in humans the relevance and the kinetics of radio-induced bio-markers in plasma and urines, previously described at the preclinical stage.

详细描述

The nuclear and radiologic risks monitoring is a major preoccupation for our society. During an accident, it is primordial to define the biologic dosimetry. The dose and distribution knowledge is crucial for the medical care. Indeed, Total Body Irradiation (TBI) and Partial Body Irradiation (PBI) do not have the same clinical outcome. A Total Body Irradiation induces an acute radiation syndrome with a Medullary Aplasia. A quick diagnostic would allow the optimization of the medical care.

Nowadays, the analyse of the chromosome with two centromeres is the current norm to estimate the radiation dose, but this technique is time consuming, and not adapted to an emergency situation, and to a large population.

The new genetic techniques could permit the quick radiation dosimetry diagnosis. The research of early exposition bio-markers seems to be of a major interest. These bio-markers would allow to rapidly define the radiations perceived by an exposed subject, before the apparition of the symptoms, and by the way, to conduct to a therapeutic strategy more adapted to the patient.

In this purpose, the present study will need blood and urines samples of patients totally or partially exposed to radiations, according to their usual medical care.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • More than 18 years old
  • For the group A:
  • Patient suffering from a malignant blood disease requiring a whole-body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, during 3 days.
  • OR For the group B:
  • Patient with one (or more) pelvis metastasis requiring radiation therapy without concomitant chemotherapy, according to the following protocol: 4 Gray per day for 5 days.

排除标准

  • More than 70 years old,
  • Subject presenting abnormal blood count (grade 3),
  • Person with a not controlled chronic illness,
  • Subject presenting an abnormal hepatic assessment (grade 3),
  • Subject having already received ionizing treatments,
  • Subject reached HIV, hepatitis C or any other progressive infectious diseases,
  • Pregnant women or nursing mothers,
  • Person under protection of justice or unable to give consent.

结局指标

主要结局

Level of haematological and biochemical markers

时间窗: Day 3

The following bio-markers levels will be calculated : * Blood count, * Pads, * Haemoglobin, * Serum iron, * Plasma urea, * Urinary urea * Total protein, * albumin * creatin kinase, * Aspartate Amino Transferase, * alkaline phosphatase, * Total cholesterol, * Triglycerides, * Plasma creatinine * Creatinine clearance, * Urinary creatinine * Blood glucose, * Citrulline, * erythropoietin, * Plasma amylase, * Myoglobin, * Troponin, * C reactive protein, * Rate of prothrombin, * Fibrinogen, * D-Dimer, * Factor-V, * Fms-like tyrosine kinase 3-Ligand.

Quantification of chromosomal aberrations

时间窗: Day 3

Quantification of chromosomal aberrations will be performed on the blood samples performed at days 0, 1, 2 and 3 after the beginning of the rays perform in the usual practice.

Detection of biochemical markers

时间窗: Day 3

The presence or absence of these markers will be notified: * Interleukin 1 * Interleukin 6 * Interleukin 8 * Interleukin 18 * Tumor Necrosis Factor alpha (TNF-alpha) * Brain-Derived Neurotrophic Factor (BDNF) * Granulocyte Colony-Stimulating Factor (G - CSF) * Serum amyloid A (SAA) * Growth Arrest and DNA Damage-inducible 45 (GADD45) * Intestinal-type Fatty Acid-Binding Protein (FABP-I) * Liver-type Fatty Acid-Binding Protein (L-FABP) * Heart-type Fatty Acid-Binding Protein (H-FABP) * Stem Cell Factor Receptor CD117

Metabolomics markers levels

时间窗: Day 2

The metabolomic levels of the following molecules will be calculated on urine samples: * 3 - Sulfate Hydroxytyrosol * 1, 6-Anhydro-beta-D-glucose * 1 - Methylnicotinamide * 2 - Hydroxyisobutyrate * 3 - aminoisobutyrate * 3 - hydroxyisovalerate * 3 - Hydroxymandelate * 3 - Indoxylsulfate * 4 - Hydroxyphenylacetate * Acetate * Acetone * Adipic acid * Alanine * Betaine * Carnitine * Choline * Cis-Aconitate * Citrate * Creatine * Creatinine * dimethylamine * Ethanolamine * Formats * Glucose * Glycine * Glycolate * Hippurate * Histidine * Hypoxanthine * Isethionic acid * Lactate * Methanol * Methylamine * N, N-Dimethylglycine * N - Acetylserotonin sulfate * N - Acetyltaurine * O - Acetylcarnitine * O - Phosphocholine * Pi-methylhistidine * Pyroglutamate * Succinate * Tartrate * Tau-methylhistidine * Taurine * Threonine * trans-Aconitate * Trigonelline * Trimethylamine N-oxide * Tyramine sulfate * Tyrosine * Tyrosol sulfate * Uracil * Robert acid * Valine * Xanthine

次要结局

  • Radiation field(Day 3)
  • Total dose of radiation(Day 3)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验